6374-24-9

Basic information

• Product Name: Thiocarbonyl-carbamidsaeure-phenylester
• Synonyms: Thiocarbonyl-carbamidsaeure-phenylester;Phenoxycarbonyl isothiocyanate
• CAS NO: 6374-24-9
• Molecular Formula: C₈H₅NO₂S
• Molecular Weight: 179.1958
• Mol File: 6374-24-9.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 65-68 °C(Press: 0.07 Torr)
• Appearance: /
• Density: 1.19±0.1 g/cm3(Predicted)
• CAS DataBase Reference: Thiocarbonyl-carbamidsaeure-phenylester(CAS DataBase Reference)
• NIST Chemistry Reference: Thiocarbonyl-carbamidsaeure-phenylester(6374-24-9)
• EPA Substance Registry System: Thiocarbonyl-carbamidsaeure-phenylester(6374-24-9)

Safety Data

• Hazardous Substances Data: 6374-24-9(Hazardous Substances Data)

Upstream product

• 333-20-0 potassium thioacyanate 
• 1885-14-9 phenyl chloroformate 
• 540-72-7 sodium thiocyanide 
• 1147550-11-5 ammonium thiocyanate 

Downstream Products

• 58902-91-3 μ-imido-1-thio-dicarbonic acid-1-O-ethyl ester-2-phenyl ester 
• 89879-65-2 3-thio-allophanic acid phenyl ester 
• 39142-40-0 phenyl N-(2-thiazolyl)-carbamate 
• 2037-81-2 5-phenoxycarbonylamino-[1,2,3]thiadiazole-4-carboxylic acid ethyl ester 
• 91955-67-8 (4-acetyl-3-methyl-isothiazol-5-yl)-carbamic acid phenyl ester 
• 59533-88-9 (5-ethoxythiocarbonylimino-4-phenyl-[1,2,4]dithiazolidin-3-ylidene)-carbamic acid phenyl ester 
• 62966-83-0 hexahydro-1,3-dimethyl-6-thioxo-1,3,5-triazin-2,4-dione 
• 139407-70-8 (1,3-Dimethyl-ureidocarbothioyl)-carbamic acid phenyl ester 
• 85975-81-1 3,5-Diethyl-3,4,5,6-tetrahydro-N-(phenoxycarbonyl)-4,6-diphenyl-2H-1,3,5-thiadiazin-2-imin 
• 85975-70-8 3-Isopropyl-N-(phenoxycarbonyl)-4-phenyl-1,3-thiazetidin-2-imin 
• 85976-02-9 4-Benzyl-N,N'-bis(phenoxycarbonyl)-1,2,4-dithiazolidin-3,5-diimin 
• 85975-74-2 N-(Phenoxycarbonyl)-3,4,4-triphenyl-1,3-thiazetidin-2-imin 
• 85975-73-1 3-Methyl-N-(phenoxycarbonyl)-4,4-diphenyl-1,3-thiazetidin-2-imin 
• 85975-72-0 3-(2,6-Dimethylphenyl)-N-(phenoxycarbonyl)-4-phenyl-1,3-thiazetidin-2-imin 

Relevant articles and documents

Synthetic method of 1,3,4-thiadiazole derivative

The invention discloses a synthetic method of a 1,3,4-thiadiazole derivative. The method comprises the following steps: (1) using hydrazine hydrate as a raw material, under the action of a catalyst, reacting with acid, to obtain a hydrazide compound I; (2) using alkyl chloroformate and thiocyanate to react in a condition of a solvent, to obtain an isothiocyanate compound II; (3) in a reaction system of the isothiocyanate compound II, adding solution containing the compound I, reacting to obtain solution containing a compound III; (4) processing the solution of the compound III by dehydrating,neutralizing, and washing, to obtain a compound IV; (5) in the conditions of an acid-binding agent and a solvent, adding alkyl halide or sulfuric acid diester into the compound IV, reacting to obtaina compound V; and (6) enabling the compound V to perform an amination reaction with primary amine, to obtain the 1,3,4-thiadiazole derivative VI. The preparation method has the advantages of green andno pollution, simple and convenient operation, higher yield, mild reaction condition and the like.

Design and synthesis of indole, 2,3-dihydro-indole, and 3,4-dihydro-2H-quinoline-1-carbothioic acid amide derivatives as novel HCV inhibitors

An efficient synthetic methodology to provide indole, 2,3-dihydro-indole, and 3,4-dihydro-2H-quinoline-1-carbothioic acid amide derivatives is described. These conformationally restricted heterobicyclic scaffolds were evaluated as a novel class of HCV inhibitors. Introduction of an acyl group at the NH2 of the thiourea moiety has been found to enhance inhibitory activity. The chain length and the position of the alkyl group on the indoline aromatic ring markedly influenced anti-HCV activity. The indoline scaffold was more potent than the corresponding indole and tetrahydroquinoline scaffolds and analogue 31 displayed excellent activity (EC50 = 510 nM) against HCV without significant cytotoxicity (CC50 >50 μM).

Isothiazole derivatives useful as anticancer agents

The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2and R3are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.